Bing Center Posters Presented at IWWM-10

The 10th International Workshop on Waldenstrom's Macroglobulinemia was held October 11-13, 2018 in New York City, USA. The following are the 8 posters presented by the Bing Center for Waldenstrom's Macroglobulinemia.

Click on the poster to download a full size PDF version. For more information about IWWM-10, please visit http://www.wmworkshop.org/

 

Ibrutinib for the Treatment of Bing-Neel Syndrome

Ibrutinib for the Treatment of Bing-Neel Syndrome

G. Itchaki, J. Paludo, S. Ansell, L. Palomba, S. Treon ,J. Castillo

 

 

CXCR4<sup>S338X</sup> clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia

CXCR4S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia

Joshua N. Gustine, Nicholas Tsakmaklis, Maria G. Demos, Amanda Kofides, Jiaji G. Chen, Xia Liu, Manit Munshi, Maria Luisa Guerrera, Gloria G. Chan, Christopher J. Patterson, Kirsten Meid, Toni Dubeau, Guang Yang, Jorge J. Castillo, Zachary R. Hunter, Steven P. Treon, and Lian Xu.

 

 

THE IMPACT OF CXCR4 MUTATION SUBTYPES IN THE RESPONSE AND PROGRESSION-FREE SURVIVAL OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA TREATED WITH IBRUTINIB

THE IMPACT OF CXCR4 MUTATION SUBTYPES IN THE RESPONSE AND PROGRESSION-FREE SURVIVAL OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA TREATED WITH IBRUTINIB

Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni E. Dubeau, Lian Xu, Guang Yang, Zachary R. Hunter, Steven P. Treon

 

 

Impact of Ibrutinib Dose Intensity on Patient Outcomes in Previously Treated Waldenstrom Macroglobulinemia

Impact of Ibrutinib Dose Intensity on Patient Outcomes in Previously Treated Waldenstrom Macroglobulinemia

Joshua N. Gustine, Kirsten Meid, Toni Dubeau, Patricia Severns, M. Lia Palomba, Ranjana H. Advani, Steven P. Treon, and Jorge J. Castillo

 

 

Patient-Reported Symptoms During Ibrutinib Holds: A Withdrawal Syndrome

Patient-Reported Symptoms During Ibrutinib Holds: A Withdrawal Syndrome

Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni Dubeau, Patricia Severns, and Steven P. Treon

 

 

TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinemia

TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinemia

Joshua N. Gustine, Nicholas Tsakmaklis, Maria G. Demos, Amanda Kofides, Jiaji G. Chen, Xia Liu, Manit Munshi, Maria Luisa Guerrera, Gloria G. Chan, Christopher J. Patterson, Kirsten Meid, Toni Dubeau, Guang Yang, Zachary R. Hunter, Steven P. Treon, Jorge J. Castillo, and Lian Xu.

 

 

Acquired von Willebrand disease in patients with Waldenström macroglobulinemia

Acquired von Willebrand disease in patients with Waldenström macroglobulinemia

Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni E. Dubeau, Patricia Severns, Steven P. Treon

 

 

Survival Rates and Clinical Characteristics of Young Patients with Waldenström Macroglobulinemia

Survival Rates and Clinical Characteristics of Young Patients with Waldenström Macroglobulinemia

Amaara Babwah, MS, Joshua Gustine, MPH, Kirsten Meid, MPH, Toni Dubeau, NP, Patricia Severns, NP, Steven P. Treon, MD, PhD and Jorge J. Castillo, MD